Featured Research

from universities, journals, and other organizations

New DNA Chip Method Could Improve Cancer Diagnosis

Date:
October 15, 1999
Source:
Whitehead Institute For Biomedical Research
Summary:
In a new study reported in Friday's Science, a team of Whitehead-led researchers reports the first systematic and objective approach for identifying and classifying tumor types. This approach exploits the hot new technology of DNA microarrays--DNA chips that can analyze the activity of thousands of genes at a time--and could be used in the future to accurately diagnose cancer subtypes and also to predict clinical outcomes.

One of the biggest challenges in cancer treatment is choosing the right regimen for a given patient. Treatment strategies work differently for different tumors. In choosing effective treatments with minimal side effects, oncologists rely heavily on biopsy reports that diagnose the tumor type involved. However, even today, cancer diagnosis is done the old-fashioned way: by observing morphological changes in biopsies under the microscope. The method suffers from serious limitations because cancer cells that look similar under the microscope can follow different clinical courses and respond differently to therapy.

Now, in a new study reported in Friday's Science, a team of Whitehead-led researchers reports the first systematic and objective approach for identifying and classifying tumor types. This approach exploits the hot new technology of DNA microarrays--DNA chips that can analyze the activity of thousands of genes at a time--and could be used in the future to accurately diagnose cancer subtypes and also to predict clinical outcomes. Moving cancer diagnosis away from visually based systems to such molecular based systems is a major goal of the National Cancer Institute.

In the study, scientists used a DNA chip to examine gene activity in bone marrow samples from patients with two different types of acute leukemia--acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Then, using a computer algorithm, also developed at the Whitehead, they identified signature patterns that could distinguish the two types. When they cross-checked the diagnoses made by the chip against known differences in the two types of leukemia, they found that the chip method could automatically discover the distinction between AML and ALL without previous knowledge of these classes.

"These results demonstrate the feasibility of cancer diagnosis based solely on gene expression and suggest a general strategy for discovering new subtypes of cancer, independent of previous biological knowledge. This is a critical first step in improving treatments for cancer patients," says Todd Golub, first author on the paper, who holds joint appointments at the Whitehead/MIT Center for Genome Research and the Dana-Farber Cancer Institute.

"The implications of this research study are tremendous," says Dr. Eric Lander, Director of the Center for Genome Research at the Whitehead Institute. "It suggests that we may be able to use DNA arrays in a variety of clinical settings for confirming diagnoses, clarifying unusual cases and measuring patients' response to drugs. It may also provide an objective way to predict clinical outcome for patients."

Distinguishing the two types of leukemia is critical for successful treatment of the disease because chemotherapy regimens for the two vary considerably. And, although the distinctions between AML and ALL are well established, no single test is currently sufficient to establish the diagnosis, researchers say. Current clinical practice involves a battery of tests, each performed in a separate, highly specialized laboratory, that have to be interpreted by an experienced pathologist.

In the study, Dr. Golub, Dr. Lander, and their colleagues set out to develop a more systematic and objective approach to cancer classification, using acute leukemia as their test case. The scientists first sought to create a so-called "class predictor" that could classify new, unknown samples based on already known differences in the two types of leukemia. Using California-based company Affymetrix's GeneChipR probe array, the scientists measured the activity of nearly 7,000 genes in the bone marrow samples of 38 patients. This provided scientists massive amounts of complex raw data. The fundamental challenge was then to find which of these 7,000 genes are important in determining cancer types, i.e. to find a signature pattern amid a sea of noise. Scientists used a computer algorithm to find differences in patterns of expression that classified the samples into the two types based on known information about AML and ALL.

Next, scientists tested whether the method could discover the distinction between the two types without prior knowledge of the two classes. This time, they used a different strategy to analyze the raw data. Scientists used a sophisticated computer algorithm called a "self-organizing map" (SOM) that takes advantage of the fact that many genes in a cell behave similarly and organizes the data into clusters with similar patterns. SOMs have been used widely in data mining, particularly for large or messy data sets like stock market data, but Whitehead scientists were the first to apply it to gene analysis.

The SOM organized the bone marrow samples into two distinct clusters based on the expression pattern of the 6,817 genes. When scientists compared the two clusters to the known AML and ALL classes, the data matched effectively, suggesting that this was a fast, viable and highly promising method for cancer diagnosis.

"Although DNA arrays have been used in expression profiling of healthy and diseased cells, this is the first time that the technology has been applied to classify cancer types," says Dr. Golub.

The scientists say that it may be possible to do this for other cancers, and they plan to investigate this in the coming months.

The study was supported in part by the Leukemia Society of America, the National Institutes of Health, and the Leukemia Clinical Research Foundation. The study was also supported by a consortium of three companies--Bristol-Myers Squibb Company; Affymetrix, Inc.; and Millennium Pharmaceuticals Inc.--that have formed a unique corporate partnership to fund a five-year research program in functional genomics at the Whitehead's Genome Center.


Story Source:

The above story is based on materials provided by Whitehead Institute For Biomedical Research. Note: Materials may be edited for content and length.


Cite This Page:

Whitehead Institute For Biomedical Research. "New DNA Chip Method Could Improve Cancer Diagnosis." ScienceDaily. ScienceDaily, 15 October 1999. <www.sciencedaily.com/releases/1999/10/991015075830.htm>.
Whitehead Institute For Biomedical Research. (1999, October 15). New DNA Chip Method Could Improve Cancer Diagnosis. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/1999/10/991015075830.htm
Whitehead Institute For Biomedical Research. "New DNA Chip Method Could Improve Cancer Diagnosis." ScienceDaily. www.sciencedaily.com/releases/1999/10/991015075830.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com
House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Uganda on Alert for Ebola but No Confirmed Cases

Uganda on Alert for Ebola but No Confirmed Cases

AFP (July 31, 2014) Uganda's health minister said on Thursday that there are no confirmed cases of Ebola in the country, but that it remained on alert for cases of the deadly virus. Uganda has suffered Ebola outbreaks in the past, most recently in 2012. Duration: 00:59 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins